8-KEarnings & ResultsLeadership ChangesExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 7, 2013)

Filed January 7, 2013For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K report on January 7, 2013, to announce preliminary fourth quarter 2012 product revenues and provide a fiscal year 2013 revenue outlook. The company reported estimated unaudited product revenues of approximately $31.6 million for Q4 2012, representing a substantial 50% sequential increase and a 51% year-over-year rise. For the full fiscal year 2012, estimated product revenues reached approximately $92.8 million, a 41% increase from 2011. Looking ahead, DexCom projected fiscal year 2013 product revenues to be in the range of $120.0 million to $130.0 million, indicating continued strong growth expectations. Additionally, the report disclosed an internal management change: Kevin Sayer, currently President, assumed the additional role of Chief Operating Officer (COO), expanding his responsibilities to include sales, marketing, and commercial functions, while his bonus target was increased. This 8-K also included a press release and cautioned investors about forward-looking statements, highlighting various risks and uncertainties related to product demand, regulatory approvals, competition, and manufacturing.

Key Highlights

  • 1Q4 2012 estimated product revenues reached approximately $31.6 million, a 50% sequential increase and 51% year-over-year increase.
  • 2Fiscal year 2012 estimated product revenues were approximately $92.8 million, up 41% from fiscal year 2011.
  • 3Fiscal year 2013 product revenue guidance provided at $120.0 million - $130.0 million, signaling strong growth expectations.
  • 4Kevin Sayer appointed to the additional role of Chief Operating Officer (COO), expanding his responsibilities to commercial functions.
  • 5Kevin Sayer's target bonus amount increased from 90% to 100% in conjunction with his expanded COO role.
  • 6The report includes forward-looking statements and a detailed list of risks and uncertainties, emphasizing potential impacts on future results.

Frequently Asked Questions

DexCom reported estimated, unaudited product revenues of approximately $31.6 million for the fourth quarter of 2012. This represented a significant 50% increase from the prior quarter and a 51% increase compared to the fourth quarter of 2011.

The company provided an estimate for fiscal year 2013 product revenue to be in the range of $120.0 million to $130.0 million, indicating continued strong growth momentum.

Yes, Kevin Sayer, who was already President, assumed the additional role of Chief Operating Officer (COO). His responsibilities were expanded to include sales, marketing, and other core commercial functions, in addition to his existing oversight of R&D, manufacturing, clinical, regulatory, and finance.

The report highlights numerous risks, including dependence on the G4 PLATINUM system, ability to increase customer orders, product performance, obtaining regulatory approvals for new products, market acceptance, economic conditions, legal and regulatory actions, R&D delays, supply chain issues, manufacturing capabilities, future funding needs, healthcare reform, reimbursement challenges, intellectual property protection (including a lawsuit from Abbott Diabetes Care), potential kickback/patient privacy violations, product liability, clinical study outcomes, and attracting/retaining key personnel.